TetraGraph clinical use and comparison presented in ASA abstract

Uppsala, 21 June 2017. Senzime AB (publ) in partnership with Dr Réka Nemes at the University of Debrecen, Department of Anesthesiology and Intensive Care, Debrecen, Hungary, reports results from the Comparative Investigation of TOF-Watch SX and the TetraGraph. 

Senzime receives ISO 13485 certification

Uppsala, June 12, 2017. Senzime AB (publ) has received ISO 13485 certification, which is an important milestone in the CE labeling process for the company's first monitoring products.

Senzime initiates clinical study with CliniSenz System

Uppsala, May 31, 2017. Senzime AB (publ) initiates a clinical trial with CliniSenz for monitoring of tissue lactate levels after surgery in patients with esophageal cancer, a disease that affects approximately 500,000 patients worldwide annually. The current treatment is mostly surgical with risk of multiple operations and increased mortality. With CliniSenz System, it is possible to monitor the healing process after surgery and detect complications at an early stage. The study has been approved by the Ethics Committee and is expected to start in the beginning of June 2017.

Senzime is granted additional patent for OnZurf Probe

Uppsala, 24 May 2017. Senzime AB’s (publ) application regarding a new Swedish patent for OnZurf Probe has been approved, strengthening Senzime’s existing patent portfolio. The Onzurf Probe is a new generation of microdialysis probes that enable organ-specific biological monitoring of various organs such and the bowel, liver and kidney after surgery. The technology makes it possible to monitor the organs’ healing process and to provide early warning signs of complications such as ischemia and anastomotic failure.

Resolutions at Senzime AB’s (publ) Annual General Meeting

Senzime AB (publ) held its annual general meeting on May 23, 2017 in the premises of Advokatfirman Lindahl on Vaksalagatan 10 in Uppsala.

Retransmitting: Senzime’s Interim report January – March 2017

Uppsala, May 23, 2017. Senzime AB’s (publ) Interim report for January – March 2017 is now available on the company’s webbsite www.senzime.com.

Senzime’s Interim report January – March 2017

Uppsala, May 23, 2017. Senzime AB’s (publ) Interim report for January – March 2017 is now available on the company’s webbsite www.senzime.com.

TetraGraph Functionality in Scientific Abstract at IARS, Washington DC

Uppsala, May 5th, 2017.  Senzime AB (publ) today announced that the scientific abstract, “Examining Awake Volunteer Pain Scores and Operator Ease of Use of a Novel Neuromuscular Blockade Monitor” is to be presented at the International Anesthesia Research Society (IARS) meeting in Washington, DC where 1200 anesthesiologists participate.

Senzimes first day of trading on Nasdaq First North

Uppsala, April 11, 2017. Senzime AB (publ) recently completed a rights issue that raised SEK 24.4 million before issue costs. Senzime has applied for listing on Nasdaq First North which has been approved with first day of trading April 11, 2017. Previously Senzime was listed on AktieTorget.

Senzime’s rights issue oversubscribed

The subscription period for Senzime AB (publ)’s rights issue with pre-emption rights for existing shareholders (the "Rights Issue") expired on 28 March 2017 and the company is pleased to announce that there has been large interest in the subscription of shares. The Rights Issue was oversubscribed to approximately 103 percent under the original offer. Thus, the company will raise approximately SEK 24.4 million before issue costs, estimated at SEK 3.1 million.